Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Capital Leases (2016 - 2024)

Lifecore Biomedical, Inc. \De\ has reported Capital Leases over the past 8 years, most recently at $3.2 million for Q2 2024.

  • Quarterly results put Capital Leases at $3.2 million for Q2 2024, changed 0.03% from a year ago — trailing twelve months through May 2024 was $3.2 million (changed 0.03% YoY), and the annual figure for FY2024 was $3.2 million, changed 0.03%.
  • Capital Leases for Q2 2024 was $3.2 million at Lifecore Biomedical, Inc. \De\, roughly flat from $3.2 million in the prior quarter.
  • Over the last five years, Capital Leases for LFCR hit a ceiling of $26.4 million in Q2 2020 and a floor of $12000.0 in Q2 2022.
  • Median Capital Leases over the past 4 years was $3.2 million (2024), compared with a mean of $7.3 million.
  • Biggest five-year swings in Capital Leases: decreased 2.67% in 2020 and later skyrocketed 26683.33% in 2023.
  • Lifecore Biomedical, Inc. \De\'s Capital Leases stood at $26.4 million in 2020, then crashed by 99.95% to $12000.0 in 2022, then skyrocketed by 26683.33% to $3.2 million in 2023, then grew by 0.03% to $3.2 million in 2024.
  • The last three reported values for Capital Leases were $3.2 million (Q2 2024), $3.2 million (Q2 2023), and $12000.0 (Q2 2022) per Business Quant data.